AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track
This article was originally published in The Pink Sheet Daily
Executive Summary
Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.
You may also be interested in...
Euthymics' Sweet Dreams Could Be Realized With $24MM Series A
The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.
Euthymics' Sweet Dreams Could Be Realized With $24MM Series A
The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.
AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing
Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas